Innoviva Specialty Therapeutics

Latest news

• FDA Approves Xacduro (sulbactam and durlobactam) for the Treatment of Serious Infections Caused by Acinetobacter
  23 May 2023
• Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
  11 May 2023
• Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
  17 April 2023
• Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
  30 November 2022
• Entasis Therapeutics Announces Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial
  18 October 2021
• Tetraphase Pharmaceuticals Announces FDA Approval of Xerava (eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
  27 August 2018
• Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections
  27 February 2018
• Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
  2 January 2018
• FDA Approves Giapreza (angiotensin II) to Treat Dangerously Low Blood Pressure
  21 December 2017
• Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections
  11 September 2017

Drugs Associated with Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.